Role of key informants and direct patient interviews in epidemiological studies of substance abuse

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 3, 2011, Pages 308-312

  Cicero, Theodore J ^a   Ellis, Matthew S ^a   Paradis, Alethea ^a   Ortbal, Zachary ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Opioid abuse; Opioids; Post marketing surveillance; Substance abuse

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OXYCODONE; TRAMADOL;

ALCOHOLISM; ARTICLE; CHRONIC PAIN; COMORBIDITY; HUMAN; INTERVIEW; OPIATE ADDICTION; PRIORITY JOURNAL; SUBSTANCE ABUSE;

ADULT; CONFOUNDING FACTORS (EPIDEMIOLOGY); EFFECT MODIFIERS (EPIDEMIOLOGY); FEMALE; HUMANS; MALE; PATIENT PARTICIPATION; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 79951996258     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2075     Document Type: Article

References (14)

1. FDA. Controlled Substances Act. Title 21 - Food and Drugs. Chapter 13 - Drug Abuse Prevention and Control. Subchapter I - Control and Enforcement. [29 April 2010].
2. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142-1154.
3. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7-22.
4. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-672.
5. Dart RC. Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend 2009; 105: S26-32.
6. Needle R, Kroeger K, Belani H, Achrekar A, Parry CD, Dewing S. Sex, drugs, and HIV: rapid assessment of HIV risk behaviors among street-based drug using sex workers in Durban, South Africa. Soc Sci Med 2008; 67: 1447-1455.
7. Ferrer RR, Balasuriya D, Iverson E, Upperman JS. Pediatric disaster preparedness of a hospital network in a large metropolitan region. Am J Disaster Med 2010; 5: 27-34.
8. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007; 23: 103-118.
9. Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring programs for surveillance-analysis of schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol Drug Saf 2010; 19: 115-123.
10. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction related surveillance (RADARS®). Pain Med 2007; 8: 157-170.
11. FDA. Guidance for Industry - Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. [29 April 2010].
12. Catalano J. Pain management and substance abuse: a national dilemma. Soc Work Public Health 2009; 24: 477-490.
13. Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. Pain Med 2009; 10: S89-S100.
14. Cicero TJ, Lynskey M, Todorov A, Inciardi JA, Surratt HL. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain 2008; 139: 127-135.